Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as an injection for intravenous use. It enhances magnetic resonance imaging of selected organs and vascular structures.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures consistent quality, regulatory compliance and reliable logistics to meet the needs of advanced imaging departments. Its global network supports timely delivery across Europe, Asia, Africa and the Americas.

Multihance is used as a gadolinium‑based contrast agent to improve MRI visualization of various organ systems. - Liver MRI: provides enhanced lesion detection and characterization in hepatic imaging. - Cardiovascular MRI: improves delineation of cardiac chambers, vessels and myocardial perfusion. - Central nervous system MRI: increases conspicuity of brain lesions, tumors and vascular abnormalities. - Musculoskeletal MRI: highlights joint structures, cartilage and soft‑tissue pathology.

Adverse reactions to Multihance are generally infrequent but may occur following intravenous administration.

Common Side Effects: - Nausea: mild and transient. - Headache: occasional. - Injection site discomfort: mild pain or warmth. - Warm sensation: brief feeling of heat. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Allergic reaction: rash, urticaria or anaphylaxis. - Nephrogenic systemic fibrosis: rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: sudden drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Pulmonary edema: fluid accumulation in lungs.

Prior to using Multihance, clinicians should evaluate patient history and follow specific safety measures. - Renal function assessment: verify adequate kidney function before administration. - Pregnancy risk: avoid use unless clearly needed; category C. - Breastfeeding guidance: consider discontinuing breastfeeding or assess risk‑benefit. - Prior contrast reaction: review history of hypersensitivity to gadolinium agents. - Concomitant nephrotoxic drugs: use caution when patients receive other renal‑affecting medications. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other agents that affect renal function or hypersensitivity risk.

Major Interactions (Avoid): - Linear gadolinium agents: concurrent use increases cumulative gadolinium exposure. - High‑dose iodinated contrast: may exacerbate renal toxicity.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): monitor renal parameters. - Diuretics: assess fluid balance and kidney function. - ACE inhibitors or ARBs: watch for additive effects on renal function.